Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Malaria kills more than half a million and affects over 225 million people every year.

Artemisinin, a compound derived from the leaves of the annual wormwood Artemisia annua, can be used as a treatment of malaria and other diseases.Following a number of groundbreaking clinical trials, Professor Sir Nick White and his colleagues successfully demonstrated the effectiveness of artemisinin in the treatment of malaria. They also pioneered artemisinin-combination therapy (ACT), the most effective and fast-acting malaria treatment in the world.

Read the full article

Similar stories

Oxford University researchers release cheap, quick COVID-19 antibody test

News

The new easy-to-produce test detects coronavirus spike-protein binding antibodies in people who have tested positive for COVID-19.

The RECOVERY Trial: One year on

News

Thanks to the ground-breaking work of RECOVERY, clinicians treating patients hospitalised with severe COVID-19 now have two treatments that are known to improve survival. From having no known effective drugs when the pandemic first erupted, patients are now offered treatments that have been robustly proven to reduce death and improve other outcomes, such as the length of hospital stay and the need for mechanical ventilation.

USA, Chile and Peru interim trial data show Oxford-AstraZeneca vaccine is safe and highly effective

News

A Phase III study of the Oxford-AstraZeneca coronavirus vaccine conducted by AstraZeneca plc in the USA, Chile and Peru has shown that vaccine is safe and highly effective, adding to previous trial data from the United Kingdom, Brazil and South Africa, as well as real-world impact data from the United Kingdom.

Professor Cecilia Lindgren appointed Director of the Big Data Institute

News

Professor Cecilia Lindgren has been appointed as the new Director of the University of Oxford’s Big Data Institute. Professor Lindgren will take up post on 1 April 2021. She succeeds Professor Gil McVean who was the founding director of the BDI, and Interim Director, Professor Martin Landray.

Professor Sarah Gilbert awarded RSA Albert Medal

News

NDM's Professor Sarah Gilbert has been awarded the Royal Society for Arts’ (RSA) Albert Medal for her work on the Oxford vaccine. Professor Gilbert is Professor of Vaccinology and the Oxford Project Leader for ChAdOx1 nCoV-19, a vaccine against the novel coronavirus, SARSCoV-2, with approval for use in many countries around the world.

World’s largest clinical trial for COVID-19 treatments expands internationally

News

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join and recruited to RECOVERY International. NDM's Peter Horby, Professor of Emerging Infectious Diseases and Global Health, and Joint Chief Investigator for the trial, said ‘The RECOVERY trial has been an enormous success, enrolling over 36,000 patients and delivering clear results on six treatments already. By building on this success through international partnership we can speed up the assessment of novel treatments, increase the global relevance of the trial results, build capacity, and reduce wasted efforts on small uninformative studies".